Therapeutic Apheresis and Dialysis
© International Society for Apheresis
Edited By: Tadao Akizawa, Wolfgang Ramlow, A. Sergio Torloni, Ken Yamaji, Hidetomo Nakamoto, Paul S. Malchesky, Angela T. Hadsell
Impact Factor: 1.532
ISI Journal Citation Reports © Ranking: 2013: 46/75 (Urology & Nephrology); 56/68 (Hematology)
Online ISSN: 1744-9987
√ Case reports: Only cases of exceptional interest and novelty are considered. For manuscripts that do not qualify, Editors may ask authors to shorten manuscripts and rewrite as Letters to the Editor.
Thank you for your interest in Therapeutic Apheresis and Dialysis. Please take a moment to consult the following instructions to help you prepare your manuscript, and feel free to contact us with any questions. To ensure fast peer review and publication, manuscripts that do not adhere to the following instructions will be returned to the corresponding author for technical revision before undergoing peer review.
To find out how to prepare your manuscript, please click on Instructions for Authors (PDF version).
If you are ready to submit an article, please click on Online Submission.
Aims and Scope: Therapeutic Apheresis and Dialysis is the official peer-reviewed English-language journal of the International Society for Apheresis, the Japanese Society for Apheresis, and the Japanese Society for Dialysis Therapy. Therapeutic Apheresis and Dialysis publishes original research articles dealing with developments in therapeutic apheresis and dialysis applications and treatment modalities, and their clinical applications worldwide for the purpose of highlighting emerging trends and reporting the efficacy and clinical outcomes of these therapies. Membership in the Societies listed above is not a prerequisite for publication. Articles are published without charge to the author except in certain circumstances, such as the publication of color figures.
Frequency: 6 issues per year.
ISSN: 1744-9979 (print), 1744-9987 (online).
Journal abbreviation: Ther Apher Dial
Types of Articles: Therapeutic Apheresis and Dialysis publishes peer reviewed Original Articles, Reviews, Case Reports, Clinical Treatment Guidelines, Protocols, and Communications information (including Letters to the Editor). Single patient Case Reports may be considered as a Letter to the Editor. For such Case Reports, no more than 500 words, 3 authors, 4 references and 1 table or figure are appropriate. We particularly welcome Letters to the Editor as they provide a means of open communication between members of the apheresis community. All articles are peer reviewed. Communications include notifications of upcoming meetings, meeting summaries, standards, announcements, and abstracts of papers presented at meetings.
Online Submission: Please submit at: http://mc.manuscriptcentral.com/tad
All articles submitted to the Journal must comply with these instructions. Failure to do so will result in return of the manuscript and possible delay in publication. Authors may submit manuscripts to Therapeutic Apheresis and Dialysis in either print or electronic format. We strongly recommend authors use the electronic submission system.
Print Submissions: The original manuscript and two copies (including tables and figures; photocopies of the original figures are acceptable for the copies) should be submitted to:
Therapeutic Apheresis and Dialysis
10 W. Erie Street, Suite 200 Painesville, OH44077, USA
Authors will receive an immediate acknowledgment of receipt and should let the Executive Editor know if receipt is not acknowledged within two weeks.
Disclosure: Authors should declare any financial support or relationships that may pose conflict of interest in the Covering Letter and Acknowledgements.
Clinical Trials Registry: We strongly recommend, as a condition of consideration for publication, registration in a public trials registry.
Randomized Controlled Trials: Reporting of randomized controlled trials should follow the guide-lines of The CONSORT Statement.
Note to NIH Grantees: Wiley-Blackwell will support our authors by posting the accepted version of articles by NIH grant-holders to PubMed Central upon acceptance by the journal. For more information visit: http://authorservices.wiley.com/bauthor/author.asp
Acceptance: The acceptance criteria for all papers are the quality and originality of the research and its significance to our readership. Except where otherwise stated, manuscripts are peer reviewed by at least two anonymous reviewers and the Editor. The Editorial Board reserves the right to refuse any material for publication and advises that authors should retain copies of submitted manuscripts and correspondence, as material cannot be returned. Final acceptance or rejection rests with the Editorial Board.
Cover Letter: Papers are accepted for publication in the Journal on the understanding that the content has not been published or submitted for publication elsewhere. This must be stated in the cover letter. The cover letter must also contain an acknowledgement that all authors have contributed significantly, and that all authors are in agreement with the content of the manuscript. Authors must declare any financial support or relationships that may pose conflict of interest. Authors must state that the protocol for the research project has been approved by a suitably constituted Ethics Committee of the institution within which the work was undertaken and that it conforms to the provisions of the Declaration of Helsinki (as revised in Tokyo 2004), available at: http://www.wma.net/e/policy/b3.htm
Do not use patients’ names, initials, or hospital numbers, especially in illustrative material. Indicate whether the institutions or a national research council’s guide for, or any national law on, the care and use of laboratory animals was followed when reporting experiments on animals.
Copyright: Authors publishing in the Journal will be asked to sign an Exclusive Licence Form. In signing the form it is assumed that the authors have obtained permission to use any copyrighted or previously published material. All authors must read and agree to the conditions outlined in the form and must sign the form or agree that the corresponding author can sign on their behalf. Articles cannot be published until a signed form has been received. As author, you remain the copyright owner of the Article, unless copyright is owned by your employer. (US Federal Government authors please note: your Article is in the public domain.) Authors must grant Wiley-Blackwell Ltd, on behalf of the International Society for Apheresis and Wiley-Blackwell, an exclusive licence to publish your article, including the abstract, in printed and electronic form, in all languages, and to administer subsidiary rights agreements with third parties for the full period of copyright and all renewals, extensions, revisions, and revivals. The Article is deemed to include all material submitted for publication with the exception of Letters, and includes the text, figures, tables, author contact details, and all supplementary material accompanying the Article.
Preparation of the Manuscript: Manuscripts should be written so that they are intelligible to the professional reader who is not a specialist in the particular field. The Editor or the Publisher reserves the right to modify typescripts to eliminate ambiguity and repetition and improve communication between author and reader. Therapeutic Apheresis and Dialysis uses US spelling and authors should follow the latest edition of Merriam–Webster’s Collegiate Dictionary. Please write in a clear, concise, direct style. Authors whose native language is not English are urged to have an English-speaking colleague review the paper.
English-language Editing: Authors for whom English is a second language may choose to have their manuscripts professionally edited before submission or during the review process. Authors wishing to use a professional English-language editing service should make contact and arrange payment with the editing service of their choice directly.
A list of suppliers of editing services is available at: http://authorservices.wiley.com/bauthor/english_language.asp
Japanese authors: http://www.wiley.co.jp/journals/editcontribute/editservlist.html
Style: Manuscripts should follow 'Uniform Requirements for Manuscripts Submitted to Biomedical Journals', as presented in Ann Intern Med 1997;126: 36-47:
Use double spacing throughout. All measurements must be given in SI units. Abbreviations should be used sparingly – only where they ease the reader’s task by reducing repetition of long, technical terms. Initially use the word in full, followed by the abbreviation in parentheses. Thereafter, use the abbreviation only. Within the manuscript, specify the manufacturer and manufacturer’s address (city, state, country) for all vital or unusual products used in experiments. Chemical substances should be referred to by the generic name only. Trade names should not be used. Drugs should be referred to by their generic names. If proprietary drugs have been used in the study, refer to these by their generic name, mentioning the proprietary name, and the name and location of the manufacturer, in parentheses. Manuscripts should be presented in the following order: (i) title page, (ii) abstract and keywords, (iii) text, (iv) acknowledgments, (v) references, (vi) appendices, (vii) figure legends, (viii) tables (including title and footnotes) and (ix) figures.
Title Page: The title page should contain: (i) the title of the article, which should be concise but informative, (ii) the full names of each author, (iii) the institutional affi liation or name of the depart ment(s), (iv) the full postal and E-mail address, and facsimile and telephone numbers of the corresponding author, and (v) a short running title (less than 40 characters, including spaces). Do not use abbreviations, commercial names or trademarks in article titles.
Abstract and Key Words: The abstract (150 words for unstructured abstracts, 250 words for structured abstracts) should state the purposes of the study or investigation, basic procedures (selection of study subjects; observational and analytical methods), main findings (specific data and their statistical significance), and principal conclusions emphasizing the new and important aspects of the study. The abstract should not contain abbreviations or references. For the purpose of indexing, five key words should be supplied in alphabetical order. The key words should be taken from those recommended by the US National Library of Medicine's Medical Subject Headings (MeSH): http://www.nlm.nih.gov/mesh/meshhome.html
Text: Authors may use these suggested subheadings to divide the sections of their manuscript: (i) Introduction, (ii) Materials and Methods (or Patients), (iii) Results, (iv) Discussion, (v) Conclusions, (vi) Acknowledgments, and (vii) References.
Acknowledgments: Acknowledgment statements should specify: (i) contributions that require acknowledgment but do not justify authorship, such as general support by a departmental chair, (ii) acknowledgments of technical help, and (iii) acknowledgments of financial and material support, which should specify the nature of the support.
References: References should be numbered consecutively in the order in which they are first mentioned in the text. Identify references in text, tables, and legends by Arabic numerals in parentheses (i.e. Vancouver system of referencing). References cited only in tables or figure legends should be numbered in accordance with the sequence established by the first identification in the text of the particular table or figure. References should be kept to a reasonable limit – not to exceed 25. Cite the names of all authors when there are six or fewer; when seven or more, list the first three followed by et al. Do not use ibid. or op cit. Reference to unpublished data and personal communications should be cited in the text only. Use the style of the examples below, which are based on the formats used by the NLM in Index Medicus available at: http://www.nlm.nih.gov
We recommend the use of tools such as EndNote or Reference Manager for reference management and formatting.
EndNote reference styles: http://www.endnote.com/support/enstyles.asp
Reference Manager reference styles: http://www.refman.com/support/rmstyles.asp
Appendices: These should be placed at the end of the paper, numbered in Roman numerals and referred to in the text. If written by a person other than the author of the main text, the writer’s name should be included below the title.
Tables: Tables should be self-contained and complement, but not duplicate, information contained in the text. Number tables consecutively in the text in Arabic numerals. Type tables on a separate sheet with a concise legend above. Column headings should be brief, with units of measurement in parentheses; all abbreviations must be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be used (in that order) and *, **, *** should be reserved for P-values.
Figures: All illustrations (line drawings and photographs) are classified as figures. Figures should be cited in consecutive order in the text. All figures must be supplied in camera-ready format. Line figures should be supplied as sharp, black and white graphs or diagrams; lettering must be included and should be sized to be no larger than the journal text. Photographs must prevent human subjects being recognized. If supplied electronically, graphics must be supplied as high resolution files (at least 300 d.p.i.), saved as .eps or .tiff. For instructions on submitting electronic artwork, please visit the online graphics resource for authors: http://authorservices.wiley.com/bauthor/illustration.asp
Color Figures: A charge of US$530/¥64,000 for the first three color figures with US$265/¥32,000 for each extra color figure thereafter will be charged to the author.
Equations: Equations should be numbered sequentially with Arabic numerals; these should be ranged right in parentheses. All variables should appear in italics. Use the simplest possible form for all mathematical symbols.
Manuscript Tracking: Author Services enables authors to track their article, once it has been accepted, through the production process to publication online and in print. Authors can check the status of their articles online and choose to receive automated emails at key stages of production so they do not need to contact the production editor to check on progress. For more details on online production tracking and for a wealth of resources, including FAQs and tips on article preparation, submission and more: http://authorservices.wiley.com/bauthor/
Proofs: The corresponding author will receive an email alert notifying them when their proofs are ready for collection from a website that hosts the proofs. It is essential, therefore, that authors supply a working E-mail address. Full instructions on how to correct and return the proof will be sent with the proof. Alterations (other than the essential correction of errors) are unacceptable at PDF stage. Acrobat Reader is required to read the PDF. This software can be downloaded (free of charge) from the following Adobe Acrobat Reader Website: http://www.adobe.com/products/acrobat/readstep.html
Offprints: A minimum of 50 offprints will be provided upon request, at the author’s expense. These paper offprints may be ordered online: http://offprint.cosprinters.com, fill in the necessary details and ensure that you type information in all of the required fields. If you have queries about offprints, please email email@example.com
Therapeutic Apheresis and Dialysis Online: For more information, visit our website: http://www.wileyonlinelibrary.com/journal/tap
The Table of Contents may be emailed directly to your desktop by registering for free via the above site.
Early View: The journal is covered by Wiley-Blackwell’s Early View service. Early View articles are complete full-text articles published online in advance of their publication in a printed issue. Articles are therefore available as soon as they are ready, rather than having to wait for the next scheduled print issue. Early View articles are complete and final. They have been fully reviewed, revised and edited for publication, and the authors' final corrections have been incorporated. Because they are in final form, no changes can be made after online publication. The nature of Early View articles means that they do not yet have volume, issue or page numbers, so Early View articles cannot be cited in the traditional way. They are therefore given a Digital Object Identifier (DOI), which allows the article to be cited and tracked before it is allocated to an issue. After print publication, the DOI remains valid and can continue to be used to cite and access the article. More information about DOIs: http://www.doi.org/faq.html